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Abstract
Background: Atypical teratoid/rhabdoid tumor (AT/RT) is a highly malignant embryonal brain
tumor that occurs mainly in early childhood. Although most of the tumors are characterized by
inactivating mutations of the tumor suppressor gene, SMARCB1, the biological basis of its tumori-
genesis and aggressiveness is still unknown.
Procedure:We performed high-throughput copy number variation analysis of primary cell lines
generated from primary and relapsed tumors from one of our patients to identify new genes
involved inAT/RTbiology. Theexpressionof the identifiedgenewas validated in29AT/RT samples
by gene expression profiling, quantitative real-time polymerase chain reaction, and immunohisto-
chemistry (IHC). Furthermore, we investigated the function of this gene bymutating it in rhabdoid
tumor cells.
Results: TEAD4 amplification was detected in the primary cell lines and its overexpression was
confirmed at mRNA and protein levels in an independent cohort of AT/RT samples. TEAD4’s co-
activator, YAP1, and the downstream targets,MYC andCCND1, were also found to be upregulated
in AT/RT when compared to medulloblastoma. IHC showed TEAD4 and YAP1 overexpression in
all samples. Cell proliferation andmigration were significantly reduced in TEAD4-mutated cells.
Conclusions:Wereport theoverexpressionofTEAD4 inAT/RT,which is a key componentofHippo
pathway. Recent reports revealed that dysregulationof theHippopathway is implicated in tumori-
genesis and poor prognosis of several human cancers. Our results suggest that TEAD4 plays a role
in the pathophysiology of AT/RT,which represents a new insight into the biology of this aggressive
tumor.
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1 INTRODUCTION
Malignant rhabdoid tumor (MRT) is a highly aggressive pediatric
embryonal tumor that can arise in any anatomic location. The most
frequent sites of origin are the kidneys and brain.1 MRT that orig-
inates in the central nervous system (CNS) is called atypical tera-
toid/rhabdoid tumor (AT/RT). AT/RT comprises approximately 1–2%of
Abbreviations: AT/RT, atypical teratoid/rhabdoid tumor; CNV, copy number variation;
CRISPR, clustered regularly interspaced short palindromic repeats; GE, gene expression; IHC,
immunohistochemistry; MB, medulloblastoma;MRT, malignant rhabdoid tumor; Q-PCR,
quantitative real-time polymerase chain reaction; TEAD4, TEA domain family 4
all pediatric brain tumors, but it is the most frequent malignant brain
tumor among infants.2,3 It shows a highly aggressive and unresponsive
nature with a median overall survival of 6–18 months despite inten-
sive multimodal therapy, including surgery, high-dose chemotherapy
with or without intrathecal chemotherapy, and radiation therapy.4–6
Recently, reports have shown that radiation therapy and intensive
multimodal chemotherapy improve the survival of patients, especially
those older than 3 years of age. However, the prognosis for the major-
ity of patients’ population, especially in infants, remains still poor.6–10
Histopathologically, AT/RT is characterized by variable amounts
of cells with classic rhabdoid phenotype, which shows eccentrically
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placed nuclei containing vesicular chromatin and abundant cytoplasm
with eosinophilic globular inclusions. Usually, these cells with rhab-
doid phenotypes are observed within areas of small undifferentiated
tumor cells. Therefore, depending on the area examined, it can be
misdiagnosed as other embryonal brain tumors such as medulloblas-
toma (MB) or a group of tumors recognized as the primitive neu-
roectodermal tumor of the CNS in former WHO classification.11,12
After the notable discovery of genomic alterations for AT/RT in the
SMARCB1 (BAF47/hSNF5/INI1) tumor suppressor gene,which is a com-
ponent of the chromatin remodeling complex switch/sucrose nonfer-
mentable (SWI/SNF),13 negative nuclear stain for SMARCB1 protein
has become the widespread procedure for diagnosis of this tumor.14
While SMARCB1 mutations are the defining genetic alterations of
AT/RT, recent collaborative studies involving large cohorts of samples
and advances in genome-wide technologies have suggested the exis-
tence of different molecular subgroups.15–17 Several groups have also
explored new potential therapeutic targets.18–22 Nevertheless, much
of the biology contributing to the development and aggressiveness of
this tumor is still poorly understood.
TEA domain family member 4 (TEAD4) is a transcriptional factor,
which is a part of the Hippo signaling pathway. The Hippo pathway is
conserved as a tumor suppressor pathway and plays a role in several
biological processes including organ size control, tissue regeneration,
cancer development, stem cell self-renewal, and differentiation.23,24
The pathway consists of two serine/threonine kinases, MST and LAT;
the transcriptional co-activators, YAP1 and TAZ; and the transcrip-
tion factors, TEAD1–TEAD4. When the Hippo pathway is activated,
the activity of YAP1 is inhibited and the expression of its downstream
genes is suppressed. Conversely, when the pathway is inactivated,
YAP1accumulates in thenucleus and forms complexeswithTEADsand
other transcription factors, promoting cell proliferation and cell sur-
vival and inhibiting apoptosis.25 Recently, several studies have found
that mutations and altered expression of a subset of the Hippo signal-
ing pathwaygenes are involved in increased cell proliferation in diverse
types of human cancers such asmelanoma, ovarian, breast, gastric, and
colorectal cancers. Some of these reports suggest that the dysregula-
tion of this pathway correlates with poorer prognosis.24,26–29
To clarify the aggressiveness of this tumor, we performed genome-
wide studies in samples from our patients including primary and
relapsed tumors after interventions and found the amplification of
TEAD4. Then, we validated the overexpression at both mRNA and
protein levels in a larger set of samples. Its transcriptional co-activator
YAP1 and downstream targets were also found to be upregulated in
AT/RT, which may indicate the active status of TEAD4. Furthermore,
we detected decrease in cell proliferation and migration in a TEAD4-
mutated rhabdoid tumor cell line. Those facts suggest that this path-
waymay have a key role on this tumor’s biology.
2 MATERIALS AND METHODS
2.1 Tumor samples
Tumor samples including fresh frozen tumor tissues and formalin-fixed
and paraffin-embedded (FFPE) tissue sections were collected from
patients diagnosedwithAT/RT andMB. The diagnoseswere confirmed
pathologically according to the current WHO criteria.11,12 Tumors
were provided by the Juntendo University Hospital (Tokyo, Japan),
Falk Brain Tumor Bank (Chicago, IL, USA), and Center for Childhood
Cancer, Biopathology Center (Columbus, OH, USA), which is a sec-
tion of Cooperative Human Tissue Network of The National Cancer
Institute (Bethesda, MD, USA). Written informed parental consents
were obtained prior to sample collection. This study was approved by
the institutional review boards of Juntendo University (IRB #2010-
014) and Ann and Robert H. Lurie Children’s Hospital of Chicago (IRB
#2009-13778). Primary AT/RT samples from 29 patients, 4 samples
from relapsed tumor tissues (Table 1), and 15MBswere included in our
studies.
2.2 Primary cell culture
Primary AT/RT cell lines were established from the primary and
relapsed tumors fromoneof our patients. Tumor tissueswereobtained
at surgery, and minced in a Petri dish, and then maintained in
Neurobasal-A Medium with 2% B-27 supplement serum free, EGF,
FGF-Basic, and Penicillin—Streptomycin–Glutamine (Thermo Fisher
Scientific, USA) at 37°C, 5% CO2.
30 Cellblocks were made using Array
Jelly (Youken-Science Co., Ltd., Japan) according to the manufacture’s
protocol.
2.3 Copy number variations (CNVs)
Genomic DNA was isolated from both primary cell lines as described
above and from the correspondent relapsed tissue using Gentra
Purgene Tissue Kit (Qiagen, Germany) according to the manufacture’s
protocol.
A total of 250 ng of genomic DNA was used to investigate
genomic alterations using the Genome-Wide Human CytoScan HD
Array (Affymetrix, USA) according to the manufacture’s protocol. The
data were analyzed with Affymetrix R© Chromosome Analysis Suite
v1.2 (Affymetrix).
2.4 In situ hybridization
In situ hybridization was performed on FFPE sections of the primary
and relapse samples from which the primary cell lines were estab-
lished, using GeneticLab QuantiGene ViewRNA kit (Affymetrix). After
deparaffinization, sections were boiled in pretreatment solution for
20 min, digested with protease for 20 min, and then hybridized with
designed probes against TEAD4 (VX1-99999-01) and YAP1 (VX6-
99999-01). Fast Blue and Fast Red substrates were used to produce
signals.
2.5 Gene expression (GE) profiling
Total RNA was isolated using Trizol Reagent (Invitrogen, USA) from
frozen tumor tissues. GE profiling was performed using Illumina HT-
12BeadChipwhole-genomeexpression arrays (Illumina,USA). All RNA
samples were treated with DNase. In vitro transcription was com-
pleted in order to synthesize biotin-labeled cDNA. A total of 1.5𝜇g of
cDNA was hybridized to each array using standard Illumina protocols.
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TABLE 1 Summary of AT/RT patients and experiments
Subgroup IHC
Age Gender Location Cell culture CNV ISH GE/Q-PCR Torchia Johann Primary Relapsed
1 6m F PF ○ ○ ○ ○ ○
2 1 y M PF ○ ○
3 9m F ST ○ ○
4 1 y F PF ○
5 9m F PF ○
6 2 y M ST ○
7 13 y M Spine ○
8 3 y F PF ○ 2 N/A ○
9 7m M N/A ○ 2 TYR ○
10 4 y M ST ○ 1 SHH ○
11 6 y M ST ○ 2 MYC ○ ○
12 2m F PF ○ 2 TYR ○
13 1 y M ST ○ 2 N/A
14 3 y F ST ○ 2 MYC
15 11m M ST ○ N/A MYC
16 7m F ST ○ 2 MYC
17 8m F ST ○ 2 MYC
18 10 y M ST ○ 1 N/A
19 N/A N/A ST ○ 1 SHH
20 N/A N/A PF ○ 1 SHH
21 7m M PF ○ N/A N/A
22 10m M PF ○ 1 SHH
23 1 y M ST ○ N/A SHH
24 12 y M Spine ○ 2 MYC
25 9m F ST ○ 1 SHH
26 11 y M N/A ○ N/A MYC
27 10m M N/A ○ 2 TYR
28 13 y M Spine ○ N/A MYC
29 7m F ST ○ N/A MYC
CNV, copy number variation; GE, gene expression; IHC, immunohistochemistry; ISH, in situ hybridization; m, months; N/A, not available; PF, posterior fossa;
Q-PCR, quantitative real-time polymerase chain reaction; ST, supra-tentorial; y, years.
Slides were scanned and analyzed using BeadStudio (Illumina). Data
were normalized using the quantile normalization procedure from the
bioconductor package, affy (www. bioconductor. org). Kyoto Encyclo-
pedia of Genes and Genomes—KEGG (http://www.kegg.jp/kegg/) was
referred to identify enriched biological functions.
2.6 Quantitative real-time PCR (Q-PCR)
A total of 1,000 ng of RNA was used to make cDNA using the high-
capacity RNA-to-cDNA Kit (Life Technologies, USA). The expression
of selected genes was validated by TaqMan GE assays (Life Technolo-
gies). The following genes were tested: TEAD4 (Hs01125032_m1),
YAP1 (Hs00902712_g1), MYC (Hs00153408_m1), and CCND1
(Hs0076553_m1). The normalized expression levels were calcu-
lated by the ΔΔCt method using the housekeeping gene GAPDH
(Hs02758991_g1) as a reference.
Q-PCR for CNVs was performed using TaqMan Copy Number
Assays (Life Technologies) according to the manufacture’s protocol.
Three TEAD4 probes were tested (Hs01275079_cn, Hs00784753_cn,
and Hs01667625_cn) and RNase P was used as a reference. The data
were analyzed with Copy Caller Software (Applied Biosystem, USA).
2.7 Immunohistochemistry (IHC)
FFPE tumor tissue sections were stained using standard immunohis-
tochemical methods with the following antibodies: polyclonal hSNF5
antibody (1:200; Novus Biologicals, USA), polyclonal TEAD4 anti-
body (1:200; Abcam, UK), monoclonal YAP1 antibody (1:200; Abnova,
Taiwan), polyclonal Ki-67 antibody (1:200, Thermo Scientific), and
polyclonal Phospho-Histone H3 antibody (PHH3) (1:5,000, Abcam).
Slide interpretation was performed independently by two investiga-
tors in a blinded fashion (MS and STS).
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2.8 Western blotting
After cells were lysate, protein concentration was calculated using
Pierce BCA Protein Assay Kit (Thermo Fisher Scientific). A total of
20 𝜇g of proteins were loaded onto an sodium dodecyl sulfate gel
and transferred to a polyvinylidene difluoride membrane. The follow-
ing antibodies were used for protein detection: monoclonal TEAD4
antibody (1:1,000, Abcam) and monoclonal GAPDH loading control
antibody (1:25,000, Thermo Fisher Scientific). Protein levels were
detected by ECL Detection Solution (Thermo Fisher Scientific) and
visualized on Bio-Rad ChemiDocMP (Bio-Rad, USA).
2.9 In vitro genome edition
We used Lentiviral-CRISPR/Cas9 (where CRISPR is clustered regu-
larly interspaced short palindromic repeats) system to mutate TEAD4
in the MON cell line. MON cell line, which was a gift from Dr. Delat-
tre (InstituteCurie, France), was established froma humanMRTof soft
tissue.31,32 Prior to the genome edition, TEAD4 copy number amplifi-
cation in MON cell line was confirmed by Q-PCR (Fig. 3A). The cells
were maintained in HyClone RPMI 1640 (Thermo Fisher Scientific)
with 10% of FBS and penicillin/streptomycin at 37°C, 5%CO2.
Lentiviral-CRISPR/Cas9 particles (Sigma-Aldrich, USA) were used
for targeted genome editing. gRNA for HPRT was used as a posi-
tive control, and scrambled gRNA was used as a negative control.
After transduction, cells were selected with puromycin for 14 days.
The transduction efficiencies were confirmed with GeneArt Genomic
Cleavage Detection kit (Life technologies) in order to detect the locus-
specific double-strand break formation and to verify the efficiency of
the genome edition.
2.10 Cell proliferation assay
Cellular proliferation was assessed by TACS MTT Cell Prolifera-
tion Assays (Trevigen, USA) according to the manufacture’s protocol.
Absorbance was measured at 540 nm using a microplate reader after
24, 48, 72, and 96 hr. Each experiment was performed in triplicate.
We also evaluated cell proliferative activity by IHC. Positive cells for
Ki-67 and PHH3 were counted in five fields with 40× magnification
in both wild-type (WT) MON cells and TEAD4-mutated MON cells
(TEAD4-mut).
2.11 Cell migration assay
Cell migrationwas assessed using a 24-well Transwell chamber system
(Corning, USA).33 After 24 hr of incubation, the cells were fixed with
formalin, stained by cresyl violet, and counted using an invertedmicro-
scope. Each experiment was performed in triplicate.
3 RESULTS
3.1 Tumor samples and primary cell cultures
Primary AT/RT samples from 29 patients (the median age at diagno-
sis was 3 years with range from 2 months to 13 years, M:F = 13:7)
F IGURE 1 Establishment of primary cell cultures derived from
primary and relapsed tumor tissue. (A and G) Hematoxylin and eosin
(H&E) staining revealed the presence of small undifferentiated cells
and focal fields of rhabdoid cells in primary and relapsed tumor tis-
sues. Characteristic rhabdoid cells were observed in insets. (B and H)
High percentage for Ki-67-positive cells (>50%) is observed in both
primary and relapse tumors. (C and I) Nuclear immunostaining of
SMARCB1 (BAF47/hSNF5/INI-1) was absent. Positive internal control
was demonstrated in the insets. (D and J) H&E staining of cultured
cells revealed the presence of small undifferentiated cells and focal
fields of rhabdoid cells demonstrating that cultured cells have similar
morphology of the corresponding primary tumor tissues. (E and K)
High proliferative status of cultured cells as demonstrated by positive
Ki-67 immunostaining (>50%). (F and L) Nuclear immunostaining of
SMARCB1 was absent in both primary and relapsed tissue derived
cells. Normal kidney tissue was stained at the same time as a positive
control for SMARCB1 (upper right) (all images: 40×; insets: 160×
digital)
and additional four samples from corresponding relapsed tumor tis-
sues were included in this study as described in Table 1. Fifteen MB
samples were included in the study (the mean age at diagnosis was 5
years with range from 0 year to 10 years, M:F= 10:5).
Primary cell lines were established from tumors of patient num-
ber 1, who was a 6-month-old female having a tumor in the poste-
rior fossa. Two months after near total removal, the tumor relapsed
during the course of high-dose chemotherapy. Radiation therapy was
performed after the second surgery, but the patient died of dis-
ease progression 6 months after her admission. From the first and
second surgeries, primary cell lineswere established. Hematoxylin and
eosin stained slides revealed extensive areas of small undifferentiated
cells and focal fields of rhabdoid cells (Figs. 1A, 1D, 1G, and 1J). In
regards to the primary cell lines, the morphological features observed
on cell block sections were consistent with the histology of the orig-
inal tumor tissue sections. The diagnoses of AT/RT were further cor-
roborated by loss of SMARCB1 nuclear expression in tumor cells with
the presence of an appropriate internal positive control (Figs. 1C and
1I). Both sections of cell blocks from established cell lines also showed
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loss of SMARCB1 nuclear expression (Figs. 1F and 1L). High prolifera-
tive activity as detected by IHC for Ki-67 was also demonstrated in all
AT/RT samples and cell lines (Figs. 1B, 1E, 1H, and 1K).
3.2 TEAD4 and YAP1 overexpression in primary cell
lines
CNVs were analyzed in the two primary cell lines, generated from pri-
mary and relapsed tumors, and in the correspondent relapsed tumor
tissue. The chromosomal regions showing amplifications or deletions
withmore than twofold differencewere selected. A total of 31 amplifi-
cation sites and 3 deletion sites were detected. Three genes including
TEAD4were amplifiedwithin all the samples (Supplementary Table S1).
Then, the mRNA levels of TEAD4 and its co-activator YAP1 were
investigated by In situ hybridization. Both primary and relapsed tumor
tissues had significantly higher expression of TEAD4 and YAP1 when
compared to normal brain tissue, but no differences between primary
and relapsed tumors were observed (P = 0.0055 and P < 0.0001,
respectively, one-way ANOVA) (Fig. 2A).
F IGURE 2 Overexpression of TEAD4 and YAP1 in AT/RT. (A) In situ hybridization for TEAD4 and YAP1 on samples from patient number 1. The
results were analyzed by counting existing dots of mRNA and comparing tumor cells to surrounding normal cells. TEAD4 and YAP1 showed signifi-
cantly higher expression in tumors, for both primary and relapsewhen comparedwith normal cerebellum (P= 0.0055 and P< 0.0001, respectively,
one-wayANOVA). (B) Gene expression analysis showed significantly higher expression of TEAD4,YAP1,MYC, andCCND1 in AT/RTwhen compared
toMB (fold changes= 1.95, 5.56, 3.56, and 15.7, respectively; ****P< 0.0001 and ***P= 0.0001,Mann–Whitney test). (C)Microarray gene expres-
sion datawere validated by quantitative real-timePCR. All of the above geneswere significantly overexpressed inAT/RT (fold changes=8.62, 17.2,
7.91, and 16.2, respectively; ***P < 0.001 and **P < 0.01, Mann–Whitney test). (D) Immunohistochemistry for TEAD4 and YAP1 from samples of
patient number 1 (40×; inset: 160×digital). TEAD4andYAP1were highly expressed inAT/RTboth primary and relapsed tumor tissues. TEAD4was
localized in nuclei and YAP1was localized in both cytoplasm and nuclei
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F IGURE 3 TEAD4-mutated MRT cell line. (A) Copy number amplification of TEAD4 is observed in MON cell line. Normal blood cells were
used as control. (B) Posttransduced images (10×, right; bright field, left; fluorescent microscope). GFP-positive cells indicated the efficiency
of transduction: 22.3%. (C) GCD assay showed two cleaved bands below the parental band in TEAD4-mutated cells, confirming genome edit-
ing. Following two sets of primers were designed. Primer 1: 3′-TGTGATCCAGAGAGGGAACC and 5′-CATTGAACCCAGGAGGAGA; primer 2:
3′-TGTGATCCAGAGAGGGAACC and 5′-TCACTTGAACCCAGGAGGAG. (D) Q-PCR shows 42% reduction of TEAD4 expression in mutated cells
and western blotting demonstrates that TEAD4 expression was suppressed in mutated cells despite the equal level of endogenous control,
GAPDH
3.3 Verification of TEAD4 and YAP1 overexpression
in an independent set of samples
To verify the TEAD4 and YAP1 overexpression, GE profiling was
evaluated in an independent set of 24 AT/RT and 15 MB samples.
The expression of both TEAD4 and YAP1 was significantly higher in
AT/RT (fold changes = 1.95 and 5.56, respectively; P < 0.0001, Mann–
Whitney test) (Fig. 2B). The correlation between expression levels and
molecular subgroups, as defined by Torchia et al.16 and Johann et al.,17
was investigated. TEAD4 expression in Torchia’s group 1 was signifi-
cantly lower than in group 2 (P< 0.0001). Johann’s ATRT-SHH showed
a tendency to express TEAD4 in lower levels when compared to ATRT-
TYR and ATRT-MYC. YAP1 was also less expressed in Torchia’s group
1 and Johann’s ATRT-SHH. The expression levels of both TEAD4 and
YAP1 did not show correlation with age, gender, or tumor location.
The expression levels of all components of the Hippo signal-
ing pathway according to KEGG were investigated. MST and LATS,
upstream kinases of the pathway, did not show differences in expres-
sionbetweenAT/RTandMB.TheexpressionofMER,KIBRA, andFRMD,
which are considered to be regulators of these kinases even though
their function in the Hippo pathway has not been revealed yet, also did
not showdifferential expression. Thedownstream targets of theHippo
pathway,MYC and CCND1, were significantly overexpressed in AT/RT
(fold changes= 3.56 and 15.7; P= 0.0001 and P< 0.0001, respectively,
Mann–Whitney test) (Fig. 2B). GE profiling was validated by Q-PCR in
8 AT/RT and 6 MB samples (fold changes = 1.95, 5.56, 3.56, and 15.7;
P = 0.0007, 0.0007, 0.0027, and 0.0047, respectively, Mann–Whitney
test) (Fig. 2C).
The protein expression of TEAD4 and YAP1 was investigated by
IHC in 16 FFPE samples of 12 patients (Table 1). All sections includ-
ing primary and relapsed tumor tissues, showed high expression of
bothTEAD4andYAP1. TEAD4was expressed almost exclusively in the
nuclei, while YAP1 expressionwas observed both in the cytoplasm and
nuclei of tumor cells. Neither the intensity of expression nor the local-
ization of both proteins differed between primary and relapsed tumors
(Fig. 2D).
3.4 TEAD4-mutatedMRT cell line by CRISPR/Cas9
Weused Lentiviral-CRISPR/Cas9 system tomutateTEAD4 in theMON
cell line. Transfection efficacywas estimatedby thepercentageofGFP-
positive cells (Fig. 3B) and genome edition was confirmed by GCD
(genome cleavage detection) assay (Fig. 3C). The result from Q-PCR
showed 42% reduction of mRNA level of TEAD4 in mutated cells, and
protein level was evaluated bywestern blotting (Fig. 3D).
3.5 Decreased cell proliferation andmigration
in TEAD4-mutatedMRT cells
Cellular proliferation was assessed by MTT assay and IHC for Ki-
67 and PHH3 antibodies. MTT assay showed statistically significant
decrease in cell proliferation in TEAD4-mut when compared with WT
at all time points (P = 0.0020, 0.0021, 0.0025, and 0.0193, respec-
tively, unpaired t-test) (Fig. 4A). IHC for Ki-67 showed high prolifer-
ation in both cell lines. However, there were significantly less Ki67-
positive cells within TEAD4-mut than withinWT (P= 0.0021, unpaired
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F IGURE 4 Cell proliferation was decreased in TEAD4-mutated MRT cell line. (A) MTT proliferation assay: significantly lower cell proliferation
was observed in TEAD4-mutated cells when compared towild-type (unpaired t-test; *P< 0.05, **P< 0.005). (B) Representative images and analysis
of Ki-67 (40×): positive percentage was significantly higher in wild-type (unpaired t-test; **P < 0.005). (C) Representative images and analysis of
PHH3 antibody (40×): mitotic activity was detected by PHH3 staining. TEAD4-mutated cells showed significantly lower mitotic activity (unpaired
t-test; *P < 0.05). (D) Transwell migration assay: significantly lower migration ability was observed in TEAD4-mutated cells (unpaired t-test,
****P< 0.0001)
t-test) (Fig. 4B). Mitotic activity, measured by PHH3 antibody, was
also significantly lower in the TEAD4-mut (P = 0.0147, unpaired t-
test) (Fig. 4C). Notably, cellular migration was significantly inhibited
in TEAD4-mut when compared with WT (P < 0.0001, unpaired t-test)
(Fig. 4D)
4 DISCUSSION
In this study, we report our finding of copy number amplification of
TEAD4 and explore the overexpression of TEAD4 and YAP1 in AT/RT.
TEAD4 and YAP1 are the key components of Hippo signaling pathway,
which has been recognized as a tumor suppressor pathway in recent
years.23,34–36 We revealed the copy number amplification of TEAD4 in
primary cell lines and correspondent relapsed tissue from a patient.
Then, we confirmed the overexpression of TEAD4 and its co-activator
YAP1 atmRNA level and at protein level in the same patient’s samples.
Finally, we validated our findings in an independent cohort of samples.
To the best of our best knowledge, this is the first time TEAD4 overex-
pression is reported in AT/RT.
In normal cells, polarity and adhesion complexes regulate
the Hippo pathway and the pathway controls organ size and
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regeneration through the inhibition of cell proliferation and promotion
of apoptosis,37–39 while in several human cancers, this pathway is
dysregulated and this dysregulation is supposed to contribute to
cancer development. Although many publications report upregula-
tion of YAP1, only a few reports describe upregulation of TEAD4 in
cancer.24,26,29 Liu et al. reported that in colorectal cancer, increased
TEAD4 expression is a result of copy number amplification.29 We also
observed copy number amplification and overexpression atmRNA and
protein levels of TEAD4 in AT/RT.
Since YAP1 cannot bind to DNA by itself, the YAP1 protein in the
nuclei is required to be co-localizedwith TEAD4 for the oncogenic acti-
vation of YAP1.23 The co-localization of TEAD4 and YAP1 in nuclei
has been correlated with poor prognosis in human malignancies such
as ovarian cancer and gastric cancer.24,26 In this study we compared
AT/RT to MB, which is the most common pediatric embryonal tumor
in the CNS and has a better outcome than AT/RT, with over 90% of
cure rates for WNT group and 40–60% for group 3.40,41 Due to the
insufficient clinical information, we could not analyze the correlation
between the expression levels and the clinical outcome in our AT/RT
cohort.
Lim et al. reported that the knockdown of TEAD4 resulted in the
reduced growth of gastric cancer cells in vitro and in vivo.24 In this
study we knocked down TEAD4 in the MON cell line, which is a well-
characterized MRT cell line, and we observed both decrease in pro-
liferation and inhibition of migration of TEAD4-mut rhabdoid cells.
Although our results are in accordancewith the literature, we appreci-
ate the fact that the use ofMONmaybe somehowcontroversial.While
some authors suggested that the differences between MRTs arising in
different locations are minimal,1 other investigator demonstrated low
overlap in GE of AT/RT and RTK.42 Knocking down TEAD4 in an AT/RT
cell line may clarify this question. Based on these findings, we suggest
that TEAD4, together with its co-activator YAP1, functions as onco-
genes andmay contribute to the biology of AT/RT.
Overexpression ofMYC and CCND1 has been extensively reported
in AT/RT.43,44 They are already well-known protooncogenes and also
downstream targets of the Hippo pathway. On the other hand, both
MYC and CCND1 are part of theWnt pathway that is known to be dys-
regulated in a subset of AT/RT.45 Recently, Johann et al. proposed the
existenceof threeAT/RTepigenetic subgroups:ATRT-TYR,ATRT-SHH,
andATRT-MYC. Each of these groups has different clinical characteris-
tics and subgroup-specific networks, granting the possibility of thera-
peutic intervention.17MYCoverexpression is themarker ofATRT-MYC
and CCND1 was proposed to be the specific enhancer for ATRT-TYR
subgroup. Neither TEAD4 nor YAP1 is included in the genetic signa-
tures or networks proposed by the authors. We used their classifica-
tion system to categorize our 24 AT/RT samples, and observed that
ATRT-SHH has a tendency to express TEAD4 and YAP1 at lower lev-
els. Anothermolecular classificationwasproposedbyTorchia et al. tak-
ing into consideration anatomical location, clinical features, and the
level of ASCL1, a gene involved in the Notch signaling pathway.16 We
observed that group 1 AT/RT, that is, ASCL1-positive, had significantly
lower expression of TEAD4 when compared to group 2. No difference
in YAP1was observed.46 CCND1was overexpressed in all our samples.
We cannot affirm, based on our results, that overexpression of MYC
and CCND1 is a direct response of TEAD4 activation, as no other com-
ponent of the pathway was found to be differentially expressed in our
samples. Furthermore, it is supposed that other cancer-related path-
ways, such as TGF-𝛽 signaling pathway andWnt signaling pathway, also
regulate the downstream targets of the Hippo pathway. Further stud-
ies are needed to investigate the effects of TEAD4 activation on the
Hippo pathway in AT/RT.
In conclusion, we report the overexpression of TEAD4 in AT/RT.
High TEAD4 expression was observed in all our cases, including pri-
mary and relapsed tumors, at both mRNA and protein levels. More-
over, our results showed thatTEAD4knockdownsignificantly impaired
proliferative activity in vitro. It is feasible to therapeutically tar-
get AT/RT by inhibiting the interaction between YAP1 and TEAD4,
as has been done in other human cancers.35 Although TEAD4 may
be an essential component of AT/RT biology, further studies are
needed to explore the functional significance of these findings and
whether the Hippo pathway is an essential component of AT/RT
biology.
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